Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week Low - Should You Sell?

Key Points

• Collegium Pharmaceutical shares hit a new 52-week low, trading as low as $23.84 and closing near $24.30, well below their 50-day and 200-day moving averages.
• Analyst sentiment remains cautiously positive: the stock has a consensus “Moderate Buy” rating and a $51 average price target, although several analysts recently lowered their targets and one downgraded the shares to “Hold.”
• The company exceeded quarterly earnings expectations, reporting $1.92 in EPS versus $1.72 expected and $199.88 million in revenue; revenue increased 6.3% year over year, while institutional investors made several recent purchases.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) hit a new 52-week low during trading on Thursday . The stock traded as low as $23.84 and last traded at $24.30, with a volume of 852658 shares. The stock had previously closed at $24.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on COLL shares. Piper Sandler reaffirmed a "neutral" rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Needham & Company LLC reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Zacks Research downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Barclays cut their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a research note on Wednesday, August 19th. Finally, Weiss Ratings cut shares of Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $51.00.

Collegium Pharmaceutical Stock Performance

The firm has a market cap of $791.21 million, a P/E ratio of 19.60 and a beta of 0.72. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The company's 50-day moving average is $32.34 and its two-hundred day moving average is $34.53.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.68 earnings per share. As a group, equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Freestone Grove Partners LP bought a new position in shares of Collegium Pharmaceutical in the second quarter worth approximately $1,611,000. Vanguard Group Inc. lifted its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company's stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. Globeflex Capital L P bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $1,915,000. Y Intercept Hong Kong Ltd purchased a new position in Collegium Pharmaceutical in the 1st quarter worth approximately $686,000. Finally, Louisiana State Employees Retirement System purchased a new position in Collegium Pharmaceutical in the 1st quarter worth approximately $463,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.